Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Vir Biotechnology ( (VIR) ) has shared an update.
On May 9, 2025, Vir Biotechnology announced 24-week post-treatment data from its MARCH Phase 2 study on tobevibart and elebsiran for chronic hepatitis B, presented at the EASL Congress in Amsterdam. The study showed HBsAg loss in 17% and 21% of participants with low baseline HBsAg levels, using the combination with or without pegylated interferon alpha. Despite the promising results, Vir has not secured a development partner for further Phase 3 trials and will streamline the final stages of the Phase 2 study, aligning with its focus on the ECLIPSE Phase 3 program for hepatitis delta and oncology initiatives. The company maintains its cash runway guidance into mid-2027.
Spark’s Take on VIR Stock
According to Spark, TipRanks’ AI Analyst, VIR is a Neutral.
Vir Biotechnology’s overall score reflects significant financial challenges, including declining revenues and profitability, despite a strong balance sheet. Technical analysis indicates a bearish trend, and valuation metrics suggest limited immediate returns. Positively, the recent earnings call highlighted strategic advancements and a strong cash position, offering some optimism.
To see Spark’s full report on VIR stock, click here.
More about Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on leveraging the immune system to develop treatments for serious infectious diseases and cancer. Their portfolio includes programs for chronic hepatitis delta and dual-masked T-cell engagers for solid tumors, along with preclinical programs for various infectious diseases and oncologic malignancies.
Average Trading Volume: 1,232,441
Technical Sentiment Signal: Sell
Current Market Cap: $774.5M
Learn more about VIR stock on TipRanks’ Stock Analysis page.